Today: 8 June 2026
Browse Category

ASX:GNC 12 November 2025 - 2 February 2026

Australia stock market sinks as ASX 200 hit by gold rout — what to watch before the RBA call

Australia stock market sinks as ASX 200 hit by gold rout — what to watch before the RBA call

Australian shares fell sharply Monday, with the S&P/ASX 200 down 1.02% to 8,778.6, its lowest close since January 12, as gold miners led declines. Spot gold slid 3.2% to $4,708 an ounce amid forced selling, while BHP dropped 2.3% and Santos lost 3.3%. The Aussie dollar slipped to $0.6924. Investors await Tuesday’s Reserve Bank of Australia rate decision.
2 February 2026
······
Westpac’s $7 Billion Windfall Ignites ASX Rally Despite Mining Slump – Nov 3, 2025

ASX Today: Australian Shares Slip 0.5% as Jobs Beat Cools Rate‑Cut Hopes; Xero Sinks, Domino’s & Lithium Surge — 13 November 2025

Australia’s S&P/ASX 200 fell 0.52% to 8,753.40 Thursday, hitting a 50-day low after jobs data showed unemployment at 4.3% and 42,200 jobs added in October. The surprise cut rate-cut bets and lifted the Australian dollar. Materials outperformed, while rate-sensitive sectors lagged. DroneShield plunged 31.4% after director share sales; Domino’s jumped 11.6% on an AGM update.
13 November 2025
········
Westpac’s $7 Billion Windfall Ignites ASX Rally Despite Mining Slump – Nov 3, 2025

ASX Pre‑Open: Futures Point Higher as Dow Hits New Record; Oil Slumps, Gold Holds Firm; Jobs Data, Xero, Orica & GrainCorp in Focus (13 Nov 2025)

ASX 200 futures rose 0.15% ahead of Thursday’s open, following a record Dow Jones close above 48,000 and weaker tech stocks on Wall Street. Oil prices dropped to three-week lows, with WTI at US$58.49 a barrel. Investors await Australia’s October labour force report at 11:30am AEDT and earnings from Xero, Orica, and GrainCorp. The Australian dollar traded near US$0.654 early.
12 November 2025
·····

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop